Zobrazeno 1 - 4
of 4
pro vyhledávání: '"JoAl G, Mayor"'
Autor:
Ariel R. Topletz-Erickson, JoAl G. Mayor, Hsu-Tai Liu, Layth I. Abdulrasool, Christopher J. Endres
Publikováno v:
Drugs in R&D, Vol 23, Iss 4, Pp 411-419 (2023)
Abstract Background and Objective Tucatinib is a selective tyrosine kinase inhibitor of the human epidermal growth factor receptor 2 (HER2) approved to treat metastatic HER2-positive breast and colorectal cancers. The International Council for Harmon
Externí odkaz:
https://doaj.org/article/7a4ad461bb6c4392b531e81c99da3f67
Autor:
Ariel R, Topletz-Erickson, Anthony J, Lee, JoAl G, Mayor, Hao, Sun, Layth I, Abdulrasool, Evelyn L, Rustia, Luke N, Walker, Christopher J, Endres
Publikováno v:
Clinical Pharmacokinetics. 61:1761-1770
Tucatinib, a highly selective tyrosine kinase inhibitor of the human epidermal growth factor receptor 2 (HER2) approved for HER2-positive metastatic breast cancer, is cleared by hepatic metabolism and subsequent biliary excretion. Liver disease can a
Autor:
Ariel Topletz-Erickson, Anthony Lee, Evelyn L. Rustia, Hao Sun, JoAl G. Mayor, Layth I. Abdulrasool, Luke Walker, Christopher J. Endres
Publikováno v:
Clinical pharmacokinetics. 61(10)
Tucatinib is approved for treatment of human epidermal growth factor receptor 2-positive metastatic breast cancer. Understanding potential drug-drug interactions (DDIs) informs proper dosing when co-administering tucatinib with other therapies. The a
Autor:
Ariel R. Topletz-Erickson, Anthony Lee, Vineet Kumar, Michelle Ubowski, JoAl G. Mayor, Layth I. Abdulrasool, Clark M. Henderson, Joseph A. Ware, Christopher J. Endres
Publikováno v:
Cancer Research. 83:5060-5060
Background: Oxaliplatin (OX)-containing regimens are frequently utilized to treat gastrointestinal (GI) cancers. OX is eliminated predominately via urinary excretion (GFR and active tubular secretion). The contribution of active transport via OCT2 an